Truist Securities on BioXcel Therapeutics (BTAI): 'Stock reaction is difficult to gauge'
Tweet Send to a Friend
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $71.00 price target on BioXcel Therapeutics (NASDAQ: BTAI).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
